Xenetic to Supply Recombinant DNase I for Evaluation as Ewing Sarcoma Treatment

FRAMINGHAM, MA / ACCESSWIRE / October 17, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) (“Xenetic” or the “Company”), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat oncology indications, today announced it has entered into a Materials Transfer Agreement with Tokyo Medical University to advance the development of its systemic DNase program. Under the terms of the agreement, Professor Takuro Nakamura of the Department of Experimental Pathology, Institute of Medical Science at Tokyo Medical University will lead the research program evaluating the effects of human recombinant DNase I (rhDNase I) when given in combination with chemotherapy in a proprietary immunocompetent preclinical mouse model of Ewing sarcoma.

Ewing Sarcoma and DNase I Treatment

Ewing sarcoma is a rare and aggressive type of cancer that primarily affects children and young adults. Current treatment options for Ewing sarcoma include chemotherapy, surgery, and radiation therapy. However, the prognosis for patients with metastatic or recurrent Ewing sarcoma remains poor.

DNase I is an enzyme that breaks down DNA, and research has shown that it may have potential in treating cancer by disrupting the DNA of tumor cells. In preclinical studies, rhDNase I has demonstrated promising anti-tumor activity when used in combination with chemotherapy.

Research Collaboration with Tokyo Medical University

The collaboration between Xenetic Biosciences and Tokyo Medical University aims to further investigate the therapeutic potential of rhDNase I in Ewing sarcoma. Professor Takuro Nakamura’s research team will utilize a unique immunocompetent preclinical mouse model to evaluate the effects of rhDNase I in combination with chemotherapy.

This research partnership represents a significant step forward in the development of novel treatment options for Ewing sarcoma and could potentially lead to improved outcomes for patients with this rare cancer.

Impact on Individuals

For individuals diagnosed with Ewing sarcoma, the evaluation of rhDNase I as a treatment option could offer new hope for improved outcomes and quality of life. This research collaboration may lead to the development of new, more effective therapies that could ultimately benefit patients battling this rare and aggressive cancer.

Global Impact

The advancement of innovative immuno-oncology technologies, such as the use of rhDNase I in combination with chemotherapy for Ewing sarcoma, has the potential to make a significant impact on the field of oncology. If successful, this research collaboration could pave the way for the development of new treatment strategies not only for Ewing sarcoma but also for other hard-to-treat oncology indications.

Conclusion

The collaboration between Xenetic Biosciences and Tokyo Medical University to evaluate rhDNase I as a treatment for Ewing sarcoma represents a promising step towards advancing the field of immuno-oncology and improving outcomes for patients with rare and aggressive cancers. This research partnership has the potential to lead to the development of new and more effective treatment options that could benefit individuals affected by Ewing sarcoma and have a broader impact on the global oncology landscape. Stay tuned for updates on the progress of this innovative research collaboration.